Overview

Extension Study to Evaluate NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label extension, interventional study to evaluate the long-term safety, tolerability, and effectiveness of NBI-827104 in pediatric subjects with EECSWS. This study will enroll subjects who completed treatment in the Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group Study NBI-827104-CSWS2010.
Phase:
Phase 2
Details
Lead Sponsor:
Neurocrine Biosciences